AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC

被引：0
|
作者：
Besse, B. [1 ]
Felip, E. [2 ]
Kim, E. S. [3 ]
Clifford, C. [4 ]
Louie-Gao, M. [4 ]
Yagui-Beltran, A. [4 ]
Popat, S. [5 ]
机构：
[1] Inst Gustave Roussy, Dept Med, Villjuif, France
[2] Vall DHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[3] Atrium Hlth, Levine Canc Inst, Dept Solid Tumor Oncol, Charlotte, NC USA
[4] Blueprint Med Corp, Cambridge, MA USA
[5] Royal Marsden Hosp, Dept Med, Lung Canc Unit, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
tyrosine kinase inhibitor; clinical trial; RET;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P87.02
引用
收藏
页码：S684 / S684
页数：1
相关论文
共 50 条
  • [31] First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC
    Wang, Lijie
    Gao, Ming
    Yang, Wenyu
    Wang, Chunyu
    Wang, Ting
    Jing, Fangfang
    Ma, Junxun
    Zhang, Fan
    Tao, Haitao
    Hu, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] LURET study: A phase II study of vandetanib, RET inhibitor in patients with advanced RET fusion-positive NSCLC
    Yoh, Kiyotaka
    Seto, Takashi
    Satouchi, Miyako
    Nishio, Makoto
    Yamamoto, Noboru
    Murakami, Haruyasu
    Nogami, Naoyuki
    Yamanaka, Takeharu
    Goto, Koichi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 91 - 91
  • [33] Phase II trial of first-line capecitabine plus cisplatin in patients with advanced/metastatic nasopharyngeal cancer (NPC)
    Chua, D.
    Ng, W.
    Yiu, H.
    Seetalarom, K.
    Kurnianda, J.
    Sze, W.
    Krishnan, G.
    Shotelersuk, K.
    Hong, R.
    Forster, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom
    Trojan, Joerg
    Cebon, Jonathan
    Liem, Andre K.
    Lipton, Lara
    Gupta, Charu
    Wu, Benjamin
    Bass, Michael
    Hollywood, Ellen
    Ma, Jennifer
    Bradley, Margaret
    Litten, Jason
    Saltz, Leonard B.
    [J]. ONCOLOGIST, 2017, 22 (07): : 780 - +
  • [35] Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC). The ACROSS Study
    Domenech, Montse
    Losa, Ferran
    Blanco, Remei
    Nogue, Miquel
    Montesinos, Jesus
    Mesia, Carles
    Gallardo, Enrique
    Perez de Olaguer, Joaquim
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 177 - 177
  • [36] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Jotte, Robert M.
    Socinski, Mark A.
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    West, Howard J.
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Cappuzzo, Federico
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
  • [37] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Possinger, K
    Kaufmann, M
    Coleman, R
    Stuart, NSA
    Helsing, M
    Ohnmacht, U
    Arning, M
    [J]. ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
  • [38] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Cappuzzo, Frederico
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    Jotte, Robert
    West, Howard
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Socinski, Mark
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297
  • [39] A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
    Qin, Hao
    Wan, Yuxiang
    Dong, Yuchao
    Sun, Qinying
    [J]. CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 765 - 769
  • [40] Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC).: Across
    Domènech, M
    Losa, F
    Blanco, R
    Nogué, M
    Montesinos, J
    Mesía, C
    Gallardo, E
    de Olaguer, JP
    [J]. LUNG CANCER, 2005, 49 : S242 - S242
12345